Compare Quantumscape Corp (QS) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quantumscape Corp vs Sanofi SA — how do they compare? Quantumscape Corp trades at $4.58 (market cap $2.82B), while Sanofi SA trades at $40.13 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 33.8× Quantumscape Corp's market cap, and Sanofi SA pays a 6.01% dividend while Quantumscape Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quantumscape Corp for 37 Days and Sanofi SA for 94 Days on average.
| QS | SNY | |
|---|---|---|
Market Cap | $2.82B | $95.18B |
Volume | 21,878,246 | 2,995,646 |
Sector | Consumer Cyclical | Health |
52-Week High | $18.44 | $52.34 |
52-Week Low | $4.52 | $39.51 |
Typical Hold Time | 37 Days | 94 Days |
Enterprise Value | $2.03B | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QuantumScape (QS) trades at $4.545, up 0.55% on the day, but remains in a bearish technical trend with significant fundamental challenges. The company continues to operate without revenue while reporting substantial losses (-$435.05M net income in 2025). Recent earnings show mixed results with two beats and one miss in the last four quarters. The stock faces headwinds from delayed commercialization timelines and insider selling activity, though institutional interest persists with Bank of New York Mellon establishing a new position.
QS represents a high-risk, speculative investment opportunity in solid-state battery technology. The primary opportunity lies in potential commercialization success with automotive partners like Volkswagen, while major risks include continued cash burn, competitive threats, and execution delays. Analyst consensus remains cautious with 73% hold ratings and a $10.35 price target suggesting 128% upside from current levels, but the path to profitability remains uncertain.
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
